BACKGROUND: Targeted anti-tumor necrosis factor (TNF) strategies in patients with rheumatoid arthritis have resulted in new and/or worsening heart failure in individuals who were free of cardiovascular disease. METHODS AND RESULTS: To determine the mechanism of new and/or worsening heart failure in patients who were receiving the soluble TNF-antagonist etanercept, we analyzed frozen plasma samples from a previous clinical trial with etanercept in heart failure patients, and conducted complimentary mechanistic in vitro studies. Analysis of the clinical trial data showed that use of etanercept resulted in a significant 70-fold increase in the level of immunoreactive TNF. Complimentary in vitro studies using an L929 bioassay showed that at low concentrations of etanercept relative to TNF there was an unexpected 1.5- to 1.75-fold increase in the absolute level of TNF bioactivity. We also examined the effect of etanercept on TNF stability and the results showed that there was a two-fold increase in the mass of bioactive homotrimeric TNF when the molar ratio of TNF to etanercept was approximately 200:1. CONCLUSION: Etanercept increases the immunoreactive mass of TNF in heart failure patients, as well as augments TNF cytotoxicity in certain settings, thus suggesting one potential mechanism for the worsening heart failure in some patients who were receiving this agent.
BACKGROUND: Targeted anti-tumor necrosis factor (TNF) strategies in patients with rheumatoid arthritis have resulted in new and/or worsening heart failure in individuals who were free of cardiovascular disease. METHODS AND RESULTS: To determine the mechanism of new and/or worsening heart failure in patients who were receiving the soluble TNF-antagonist etanercept, we analyzed frozen plasma samples from a previous clinical trial with etanercept in heart failurepatients, and conducted complimentary mechanistic in vitro studies. Analysis of the clinical trial data showed that use of etanercept resulted in a significant 70-fold increase in the level of immunoreactive TNF. Complimentary in vitro studies using an L929 bioassay showed that at low concentrations of etanercept relative to TNF there was an unexpected 1.5- to 1.75-fold increase in the absolute level of TNF bioactivity. We also examined the effect of etanercept on TNF stability and the results showed that there was a two-fold increase in the mass of bioactive homotrimeric TNF when the molar ratio of TNF to etanercept was approximately 200:1. CONCLUSION: Etanercept increases the immunoreactive mass of TNF in heart failurepatients, as well as augments TNFcytotoxicity in certain settings, thus suggesting one potential mechanism for the worsening heart failure in some patients who were receiving this agent.
Authors: James P Utz; Andrew H Limper; Sanjay Kalra; Ulrich Specks; John P Scott; Zvezdana Vuk-Pavlovic; Darrell R Schroeder Journal: Chest Date: 2003-07 Impact factor: 9.410
Authors: K M Mohler; D S Torrance; C A Smith; R G Goodwin; K E Stremler; V P Fung; H Madani; M B Widmer Journal: J Immunol Date: 1993-08-01 Impact factor: 5.422
Authors: Douglas L Mann; John J V McMurray; Milton Packer; Karl Swedberg; Jeffrey S Borer; Wilson S Colucci; Jacques Djian; Helmut Drexler; Arthur Feldman; Lars Kober; Henry Krum; Peter Liu; Markku Nieminen; Luigi Tavazzi; Dirk Jan van Veldhuisen; Anders Waldenstrom; Marshelle Warren; Arne Westheim; Faiez Zannad; Thomas Fleming Journal: Circulation Date: 2004-03-15 Impact factor: 29.690
Authors: C J Fisher; J M Agosti; S M Opal; S F Lowry; R A Balk; J C Sadoff; E Abraham; R M Schein; E Benjamin Journal: N Engl J Med Date: 1996-06-27 Impact factor: 91.245
Authors: Eugene S Chung; Milton Packer; Kim Hung Lo; Adedigbo A Fasanmade; James T Willerson Journal: Circulation Date: 2003-06-09 Impact factor: 29.690
Authors: Ashmeetha Manilall; Lebogang Mokotedi; Sulè Gunter; Regina Le Roux; Serena Fourie; Colleen A Flanagan; Aletta M E Millen Journal: Physiol Rep Date: 2021-11
Authors: Sulè Gunter; Frederic S Michel; Serena S Fourie; Mikayra Singh; Regina le Roux; Ashmeetha Manilall; Lebogang P Mokotedi; Aletta M E Millen Journal: PLoS One Date: 2022-02-25 Impact factor: 3.240
Authors: Gareth J Padfield; Jehangir N Din; Elena Koushiappi; Nicholas L Mills; Simon D Robinson; Nicholas Le May Cruden; Andrew John Lucking; Stanley Chia; Scott A Harding; David E Newby Journal: Heart Date: 2013-04-10 Impact factor: 7.365